Guaranteed adherence. Better outcomes.™
Through miniaturized, long-term biopharmaceutical implants, we seek to free patients from medication adherence challenges, minimizing the burden and maximizing the benefit of clinical treatments.
Addressing the biggest challenges in chronic disease treatment – medication non-adherence and tolerability.
An alarming percentage of patients suffering from chronic illnesses don’t take their medications as prescribed, often due to the inconveniences associated with drug administration and/or tolerability, which may be associated with fluctuating drug levels.
Hear from our CEO, Dr. Adam Mendelsohn, on our revolutionary approach to challenges associated with patient behavior.Our long-term solution for life-long conditions.
Our Lead Drug Candidate: NPM-119
GLP-1 Receptor Agonist
NPM-119 is a miniature, subdermal, exenatide drug implant designed to treat the growing number of patients with type 2 diabetes. This device can be conveniently inserted under the skin during a quick outpatient procedure and is designed to provide steady doses of medication for up to six months.
Starting Soon: Our First NPM-119 Clinical Study
We are currently preparing to initiate LIBERATE-1™, a Phase 2, First-in-Human clinical study of NPM-119 in patients with type 2 diabetes for a 12-week treatment period.
